# PsyMed Ventures

PsyMed Ventures is a Venture Capital based in San Francisco, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** www.psymed.ventures
- **LinkedIn:** https://www.linkedin.com/company/psymed-ventures

## Regulatory record

- **CRD number:** 317621
- **SEC file number:** 802-135713
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/317621

## About

PsyMed Ventures is a frontier brain and mental health venture capital fund. It funds and supports founders elevating brain and mental health through innovative neuroscience and frontier technologies. It invests in frontier technologies transforming the mental and brain illness epidemic into a flourishing future. PsyMed founders align healing, responsibility, and profitability.

## Sectors

- Digital Health
- AI/ML
- Healthcare Services

## People

- Matias Serebrinsky — General Partner & Co-Founder
- Greg Kubin — General Partner & Co-Founder
- Dina Burkitbayeva — Co-Founder
- Tim Gardner — Venture Partner
- Negin Mokhtari — Venture Partner

## Questions

### Who leads investment decisions at PsyMed Ventures?

General Partners and co-founders Matias Serebrinsky and Greg Kubin lead investment decisions. Serebrinsky brings experience running Nvidia Inception in North America and co-founding CookUnity, while Kubin previously co-founded a SaaS platform and personally invested in over 20 mental health companies. Dina Burkitbayeva, the third co-founder, focuses on portfolio operations as CEO of Freedom Biosciences. The firm's investment committee is supplemented by venture partners with technical neuroscience background.

### How does PsyMed Ventures source its deal flow?

PsyMed sources through a combination of academic neuroscience networks, operator referrals from its podcast 'Business Trip', and relationships with incubators and accelerators in the neurotech space. Venture Partner Tim Gardner, a founding Neuralink member, provides direct access to brain-computer interface and bioengineering talent. The firm's public content and newsletter platform serve as an inbound magnet for founders operating at the intersection of AI, digital health, and psychiatry.

### Which therapeutic areas does PsyMed Ventures emphasize?

PsyMed concentrates on neuropsychiatry, neurodegeneration, and mental health broadly. This includes RNAi medicines (Aerska), non-hallucinogenic psychedelics (Delix Therapeutics), bioelectronic interventions (Motif Neurotech), and digital therapeutics for ADHD (Neurode). The firm also invests in peripheral modalities that affect brain health, such as metabolic psychiatry and holistic medicine.

### What is the relationship between PsyMed Ventures and its podcast 'Business Trip'?

Business Trip is co-hosted by general partners Matias Serebrinsky and Greg Kubin. The podcast explores the future of mental health and wellness and operates as both a public education platform and a deal-flow engine. It reinforces PsyMed's positioning as a thematic investor by surfacing emerging research, products, and founders to a specialist audience.

## Related profiles

- [PSS](https://altss.com/profile/pss)
- [PTB Ventures](https://altss.com/profile/ptb-ventures)

---

Last updated: 2026-08-11T15:07:49.000Z

Canonical page: https://altss.com/profile/psymed-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology